Hypertension, Renovascular

Demand for renal denervation procedures is anticipated to be aided by various authorities and government organizations increasing funding for R&D initiatives for renovascular hypertension treatment. Fact.MR – A Market Research and Competitive Intelligence Provider: Renal Denervation technologies have witnessed impressive growth in the past due to surge in prevalence of hypertension patients. Moreover, market is also driven by its minimally-invasive procedure for hypertension treatments. Renal denervation is a microsurgical solution for hypertension. Radiofrequency ablation is the process that helps burning the neurons in the renal arteries. Once blood pressure is reduced, nerve stimulation is decreased. This is commonly used to get better results when drug treatment hasn't worked to relieve symptoms. With the help of ultrasound or radiofrequency pulses, the nerves that line the renal artery wall are destroyed. Moreover, a reduction in sympathetic kidney activity lowers blood pressure. Also, the renal denervation devices are expected to witness high demand due to rising prevalence of chronic disorders including obesity in both, children and adults. As per the statistic from World Health Organization (WHO), more than 39 million children under the age of five were overweight in 2020. Also, high leptin levels in obese individuals might lead to hypertension by stimulating the formation of blood vessels in the hypothalamus. For more insights into the Market, Request Brochure of this Report However, inadequate clinical data is one of the factors restricting the growth of renal denervation technologies market, which makes it challenging to obtain regulatory body approval for new products. Moreover, market is also restricted due to lack of skilled professionals. Moreover, risk of infection following surgery is one of the main concerns that can limit the demand. But, introduction of new products in this area is expected to aid the expansion of the market. Also, the surge in prevalence of drug-resistant hypertension cases in various regions such as North America, Europe could drive the growth of the market. Market Trends: Surge in funding for treatment of renal disorders Various government authorities and organizations are increasing funding for R&D initiatives for renovascular hypertension treatment. Moreover, advancements in the devices could also fuel the growth of the industry. Apart from this, various factors that are boosting the adoption of the renal denervation method is that it lessens the renal artery injury. Various patients because of its effectiveness prefer this method. Moreover, government organizations are incorporating technology into these kinds of health practices and also offering opportunities in renal denervation industry. For Comprehensive Insights Ask An Analyst Here New entrants attempting to create reliable systems New market entrants are focusing on technological advancements in Renal Denervation Technologies. Moreover, new companies are continuously focus on reliable systems for reducing the difficulties associated with high blood pressures and hypertension. For instance, A start-up based in Israel – SoniVie - received FDA approval for its novel treatment for hypertension. Moreover, patients with hypertension can benefit from renal artery denervation using the advanced ultrasound technology TIVUS. Moreover, the main treatment made available by TIVUS, renal denervation, is a minimally invasive surgery that safely ablates renal artery nerves using high frequency, non-focused ultrasound energy. Moreover, this process lowers blood pressure by reducing nerve activity. Regional Market Growth Avenues Europe is expected to dominate the renal denervation technologies market. As per a research study, Over 40% of Europeans over the age of 25 have hypertension, and 10% of those have medication-resistant hypertension. Moreover, numerous renal denervation activities with CE authorization are available in Europe. Also, growing R&D efforts to create effective technologies for renal artery stenosis are the main drivers boosting the market expansion. In the meanwhile, increased incidences of uncontrolled hypertension, changing lifestyle among the populace are expected to fuel market expansion in the US. Also, rapid growth of uncontrolled hypertension caused by rapid urbanization, and an increase in FDA approvals are major factors contributing to the market growth in the United States. Get Customization on this Report for Specific Research Solutions More Insights Available Fact.MR offers a unique perspective and actionable insights on the coatings for Renal Denervation Technologies Market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021 – 2031. The research study is based on the basis of Product (Symplicity, Vessix, EnligHTN, ParadiseI, beris & Others) By Technology (Radiofrequency-based, Ultrasound-based & Micro-infusion-based) By End-User and By Region – Global Market Insights 2022 to 2026 Explore Fact.MR’s Coverage on the Healthcare Domain Renal Artery Stenosis Treatment Market - Renal artery stenosis is the narrowing of the renal artery that carries blood to the kidneys. The narrowing of the renal artery obstructs blood flow, resulting in renovascular hypertension, high blood pressure, and kidney damage. Atherosclerosis and fibromuscular dysplasia are the major causes of renal artery stenosis. Renal Artery Embolization Market - The renal arteries take a large volume of blood to be filtered by the kidneys. The renal artery embolization technique is used mainly to treat urological and neurological diseases. The renal artery embolization technique is a minimal invasive procedure that terminates the blood flow completely or partially. Renal Drugs Market - Renal diseases are becoming a significant health issue among the general population. Renal drugs are majorly used for kidney disease treatment. The treatment for kidney diseases totally depends on the stage of chronic kidney disease. The main treatments which are generally provided for chronic kidney disease are lifestyle changes, renal drugs, dialysis, and kidney transplantation. Renal Denervation Technologies Market - Demand for radiofrequency-based technology is expected to increase at 35% CAGR over the coming years. It is anticipated that the excellent efficacy of radiofrequency-based technology, which has been demonstrated in various trials, would boost the significance of these devices across geographies. About Fact.MR Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. 80% of Fortune 1000's trusts us in critical decision making. We provide both qualitative and quantitative research, spanning market forecast, market segmentation, competitor analysis, and consumer sentiment analysis. Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Follow Us: LinkedIn | Twitter

Technological Innovations Leading To An Increase In Number Of New Product Launches Will Stimulate The Vascular Closure Device Market Expansion Benefit of Active Closure Devices In Shortening Of Ambulation Period Will Spur The Market Demand With High Product Adoption Fact.MR – A Market Research and Competitive Intelligence Provider: Demand for vascular closure devices is projected to increase at a CAGR of 6.6% from 2022 to 2026, as per this new Fact.MR research study. Lifestyles have changed drastically over the past few years and this has resulted in an increased incidence of cardiovascular disorders. Worldwide sales of vascular closure devices are predicted to increase at a noteworthy CAGR of 6.6% from 2022 to 2026. At present, the global vascular closure devices market stands at a valuation of US$ 834 million and is anticipated to reach US$ 1.1 billion by the end of the study period. The growth in this market can be attributed to the large number of approvals for vascular closure devices, high prevalence of cardiovascular diseases, increasing prevalence of obesity, increasing focus of market players on large-bore vascular closure devices, growing geriatric population, favourable reimbursement scenario for interventional radiology procedures, and rising focus on effective blood loss management in patients during surgeries. The report anticipates that during the forecast period, the global demand for clip VCDs will surge robustly, and register a CAGR of 6%. The demand for plug-based VCDs will also gain similar traction, while haemostasis pads will be observed as the largest-selling product in the global vascular closure device market through 2022. For more insights into the Market, Request Brochure of this Report Key Takeways from Market Study- Vascular closure devices are costly and are usually priced between US$ 150 to US$ 300; hence, their use results in high expenditure for healthcare organizations as well as patients. Increasing prevalence of several types of complications in cardiovascular surgeries has led to the high demand for cardiac solutions and devices that help in improving patient outcomes. The market for vascular closure devices in North America currently accounts for a dominant market share and this trend is expected to be rife across the forecast period. The United States and Canada are projected to be the leading markets in this region through 2026. Sales of vascular closure devices in Canada are predicted to increase at a CAGR of 6.2% over the next four years. The demand for vascular closure devices in Germany is slated to rise at a CAGR of around 6% from 2022 to 2026. Other noteworthy markets in the European region are expected to be Italy, France, and the United Kingdom. The vascular closure devices market in Latin America is anticipated to witness evolution at a CAGR of around 5% across the forecast period. The Asia Pacific region is expected to be a highly rewarding market for suppliers of vascular closure devices by the end of the forecast period as investments in the healthcare industry increase and the incidence of cardiovascular diseases rises. Currently, the vascular closure devices market in the U.S. accounts for a valuation of US$ 342 million. COVID-19 impact on the vascular closure devices market The COVID-19 outbreak negatively impacted the vascular closure devices market in 2020 due to nationwide lockdowns, denied wound care services, and canceled or postponed elective surgeries. Elective surgeries were being denied (canceled/postponed) to reserve or redirect the available limited capacities and resources (like hospital beds and patient care professionals) towards COVID-19 patient care. Manufacturers of these products have a chance to capitalize on this increased demand for medical supplies to ensure adequate and continuous supply of personal protective equipment in the market. Attributed to such factors, COVID-19 is expected to have a significant impact on the gamma probe device market. In addition, various countries had enforced lockdowns and curfews to curb the rising number of COVID-19 cases. Due to these lockdowns, patients were not able to visit hospitals, OPDs, or clinics. This temporary denial of non-emergent healthcare services is expected to limit the growth of the vascular closure devices market. However, the demand for vascular closure devices is expected to rise in the coming years. For Comprehensive Insights Ask An Analyst Here Competitive Landscape: Vascular closure device manufacturers are anticipated to focus on novel product innovation and are expected to fast-track the launch of these new products to increase their sales potential. In September 2021, Haemonetics Corporation, a renowned medical technology company, announced the launch of the VASCADE MVP® Venous Vascular Closure System. In May 2022, Teflex Incorporated, a specialty surgical instrument manufacturer, announced that its Manta vascular closure device received approval from Health Canada. With this approval, Teflex is expected to commercialize and launch the Manta closure device for Canadian patients. Key Segments in Vascular Closure Devices Industry Research By Type: Active Approximators Passive Approximators External Hemostatic Devices By Access: Femoral Radial By Procedure: Interventional Cardiology Interventional Radiology/Vascular Surgeries By Region: North America Latin America Europe East Asia South Asia & Oceania MEA Recent Developments In 2021, Vivasure Medical Ltd. (Ireland) announced the development of its product, PerQseal Blue. This product is a large-bore vascular closure device used after interventional cardiovascular procedures. In 2021, Abbott (US) acquired Walk Vascular, LLC (US) to expand its portfolio of peripheral vascular devices. In 2020, Teleflex Incorporated (US) acquired Z-Medica, LLC (US), an industry-leading manufacturer of hemostatic products that will lead to revenue growth for the company by expanding its product portfolio in the Interventional segment. In 2018, Cardinal Health (US) launched MYNX Control, a sealant or gel-based device with extravascular sealing and resorbability properties. Get Customization on this Report for Specific Research Solutions Key benefits of the report: This study presents the analytical depiction of the vascular closure devices market along with the current trends and future estimations to determine the imminent investment pockets. The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the vascular closure devices market share. The current market is quantitatively analyzed from 2020 to 2027 to highlight the vascular closure devices market growth scenario. Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. The report provides a detailed analysis based on competitive intensity and how the competition will take shape in coming years. Questions answered in the vascular closure devices market research report: Which are the leading market players active in the vascular closure devices market? What are the current trends that will influence the vascular closure devices market in the next few years? What are the driving factors, restraints, and opportunities of the vascular closure devices market? What are the projections for the future that would help in taking further strategic steps? Explore Fact.MR’s Coverage on the Healthcare Domain Vascular Dressings Market - Vascular dressings are the dressing used for protection of vascular site having injury. Vascular dressings are also known as intravenous site dressings as these are used to prevent infections that can occur in the insertion site. These are important since the IV sites are prone to bacterial and viral infections. Vascular Patches Market - Vascular patches are the microporous patch of bio-compatible polyester-urethane patches which are used for vascular surgeries for suturing closure. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of deaths, claiming approximately 17.9 million lives every year. Vascular patches are highly biocompatible, minimally infectious, low suture line bleeding by its highly elastic material and excellent incorporation of tissue and doesn’t require impregnation or pre-clotting and favorable handling properties. Vascular Grafts Market - Demand for endovascular aneurysm repair treatment is expected to rise at 6% CAGR over the forecast period. Increasing need for less invasive procedures and rising popularity of stent grafts to treat atherosclerosis are major factors driving the demand for endovascular aneurysm repair surgery procedures. Peptide Based Cardiovascular Therapeutics Market - Cardiovascular disease is the leading cause of mortality and morbidity all over the world. In the past, the development of peptides as therapeutic agents had been avoided by pharmaceutical industry due to their low stability, rate of degradation and poor delivery. Intravascular Temperature Management Systems Market - The growth of the intravascular temperature management system market is mainly attributed to the increasing prevalence of cardiovascular diseases and needs of appropriate medical devices for the treatment. Peripheral Artery Revascularization Market - Peripheral artery disease (PAD) is a blood circulation disorder due to buildup of plaque in the arteries that supply blood to the peripheral organs such as legs, arms, and others organs apart from brain and heart. Patients with PAD are at the higher risk for major atherothrombotic events such as stroke and myocardial infarction. Cardiovascular Pledgets Market - Cardiovascular pledgets are utilized as support for sutures and provide maximum support for sutures and reinforce the cardiac tissue. Synthetic cardiovascular pledgets are manufactured using polytetra fluoro ethylene (PTFE) and are also known as Teflon pledgets. Renovascular Hypertension Treatment Market - Renovascular hypertension can be defined as high blood pressure caused by renal artery diseases mainly due to the narrowing of the renal artery. Renal artery diseases, such as renal artery stenosis, result in reduced blood flow due to the narrowing of the artery that provides blood to the kidney. About Fact.MR Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. 80% of Fortune 1000's trusts us in critical decision making. We provide both qualitative and quantitative research, spanning market forecast, market segmentation, competitor analysis, and consumer sentiment analysis. Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Follow Us: LinkedIn | Twitter

Fact.MR, a global research & consulting firm, in their updated edition of the report, indicated that the radiation nephropathy treatment and management market is slated to record a sturdy growth pace in 2021 and beyond. Growing number of patients experiencing diabetes and cholesterol are also projected to generate higher demand of radiation nephropathy treatment & management. Additionally, combined prevalence of key renal ailments such as, focal segmental glomerulosclerosis, atherosclerosis, and renal artery stenosis is furthermore one of the prime aspects driving the industry’s growth. “Surge in clinical trial for drug development together with the support of government organization is anticipated to bolster the expansion of radiation nephropathy treatment & management industry.” states Fact.MR. Rising Prevalence for Kidney Disorders will Encourage Industry Growth The radiation nephropathy treatment & management industry is primarily fuelled by growing prevalence of kidney disorders and growing patient population experiencing renovascular hypertension. In U.S. about, 661,000 American have kidney failure in 2013 and over 47,000 Americans died from kidney ailment. Additionally, government initiatives to boost awareness regarding early radiation nephropathy treatment & management, will be fuelling the the industry. For example, public and private healthcare organization is progressively taking initiatives for management of kidney diseases which will encourage the industry growth. Request a report sample to gain comprehensive market insights at ACE Inhibitor to Remain Lucrative Angiotensin-converting enzyme (ACE) inhibitor is projected to contribute huge revenue share in radiation nephropathy treatment and management industry. These drugs also enhance the survival rate of individuals who have lasted heart attacks as well as they avert early death of individuals from diverse ailments. Oftentimes ACE inhibitors are joined with other drugs for treating a condition. Furthermore with ACE inhibitor, diuretic drugs and angiotensin II receptor blockers are also prescribed to control the renal hyper. How huge is the Opportunity will be in the US? The US and the UK are anticipated to be the lucrative regions in the radiation nephropathy treatment and management industry due to huge patient pool. China, India and South Korea is likely to expand at a higher CAGR as a result of the growing healthcare expenditure as well as increasing healthcare facilities. Get Customization on this Report for Specific Research Solution Development of Novel Radiation Nephropathy Management & Treatment Drugs Remain Key Focus Area: Fact.MR Survey The radiation nephropathy treatment and management market appears to be greatly fragmented in nature with the existence of several manufacturers. Fact.MR’s survey indicated that the key market players are focusing on conducting clinical trials for the expansion of novel radiation nephropathy management and treatment drugs. The updated edition of the report offers comprehensive coverage of the projected remain key strategies of the market players. Some of the major market players profiled in the report are Par Pharmaceutical Companies, Inc., Silvergate Pharmaceuticals, Inc., Pfizer Inc., Merck & Company, Inc., Novartis AG, AstraZeneca plc., Johnson and Johnson, Novartis Pharmaceuticals Corporation, Eli Lilly and Company, Bayer AG, Sanofi SA, ALEMBIC PHARMS LTD, Teva Pharmaceutical Industries Ltd. and Daiichi Sankyo GlaxoSmithKline plc. The latest edition also provides a thorough analysis of the COVID-19 impact on this market. Explore Fact.MR’s Healthcare Reports Th17 Driven Disease Treatment Market: Delve into Fact.MR’s extensive study on the Th17 driven disease treatment market, offering detailed assessment. The study analyses crucial trends that are currently determining, and those which are expected to shape future expansion trajectory, shedding light on the vital dynamics such as drivers, restraints and opportunities. Closed Blood Sampling Systems Market: The global rapid oral fluid screening devices market study published by fact.mr incorporates detailed assessment of the market landscape, taking into consideration value chain analysis, business execution and supply chain analysis across key markets. PDA Closure Devices Market: Fact.MR’s global peptide based metabolic disorders therapeutics market research report provides stakeholders with an exhaustive analysis on key market dynamics, such as the drivers, restraints, opportunities and trends responsible for shaping the future expansion trajectory. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.